Strategic partnerships Neopharm is an exclusive Israeli distributor with a track record of partnering with leading global medical manufacturers, suggesting potential for new exclusive distribution deals or co-marketing arrangements with additional innovative device makers.

ALS and specialty focus Recent exclusive license and distribution deals for ALS therapy AMX0035 and other specialized therapies indicate a capability and appetite for niche, high-value indications that can be expanded to similar CNS or neurodegenerative and urology/oncology products.

Gummy supplements to devices Collaboration with TopGum to launch a local supplement brand demonstrates a readiness to diversify product categories and leverage consumer-facing brands, suggesting opportunities to bundle consumer health devices with associated consumer wellness products.

Regulatory and market access Active efforts to pursue regulatory approvals and commercialization in Israel for new therapies (Jelmyto, AMX0035) imply a capability to navigate local regulatory processes, enabling faster time-to-market for new devices or combination products.

Mid-market revenue potential With revenue in the lower-to-mid single-digit millions and an established sales force, Neopharm can scale through incremental product launches, strategic line expansions, and upsell of advanced, high-margin medical devices to Israeli hospitals and clinics.